Stay updated with breaking news from Contract Testing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owned subsidiary of WuXi AppTec – today announced the opening of its new process development...
WuXi AppTec acquires UK gene therapy company Oxgene WuXi AppTec has completed its acquisition of Oxgene, a UK contract research and development organization that designs and develops scalable gene therapy technologies. Oxgene – which will retain its name – will become a fully-owned subsidiary of WuXi Advanced Therapies (WuXi ATU): which is Shanghai-headquartered Wuxi AppTech’s cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) business unit. It will be the unit’s first facility in Europe. Scaling up tech Oxford biot...